Virus-directed enzyme prodrug therapy (VDEPT) is an emerging strategy against cancer. Our approach is a P450-based VDEPT that consists of using cyclophosphamide (CPA) as a prodrug and a Cytochrome P450 2B6/NADPH cytochrome P450 reductase fusion protein (CYP2B6/RED) as a prodrug-activating enzyme. Due to the heterogenous expression of proteins in tumor cells, basal reductase activity may not be sufficient to supply CYP2B6 with electrons, the fusion protein should enable the expression of both proteins at high levels in tumor cells. CYP/RED fusion proteins have never been previously expressed in mammalian cells, to enable expression the fusion protein was cloned into an adenoviral vector and subsequently several pulmonary tumor cell lines were infected. The CYP2B6/RED fusion protein was detected by Western blot, its mRNA by Northern blot, and its heme incorporation into an active form by spectral analysis. Infection with the fusion gene increased RED activity in microsomes by a factor of 3 compared to the control. After infection and treatment with CPA, in cell lines with low endogenous RED, the fusion protein mediated significantly higher CPA-induced cytotoxicity compared to cells expressing solely CYP2B6. In conclusion, the fusion protein is functional for VDEPT by providing one protein for higher levels of CPA metabolism. Cancer Gene Therapy ( 1,2 is an emerging strategy used to improve the selectivity of cancer chemotherapy. This is accomplished through tumor-specific activation of noncytotoxic prodrugs to active drugs by drug-metabolizing enzymes. The general scheme consists of transfection of tumor cells with an enzyme responsible for the bioactivation of a noncytotoxic prodrug and treatment with the prodrug: only cells expressing the transfected drug-metabolizing enzyme can metabolize the prodrug into cytotoxic metabolites, leading to cell death. The use of viral vectors for transgene introduction is more specifically referred to as virusdirected enzyme prodrug therapy (VDEPT). Following promising early results of a P450-based GDEPT strategy, 3 using the rat 9L gliosarcoma cell line, cyclophosphamide (CPA) as a prodrug and CYP2B1 as the prodrug activating enzyme, our approach was to improve the strategy by activating CPA with cytochrome P450 2B6 (CYP2B6) 4,5 or a CYP2B6/NADPH cytochrome P450 reductase (RED) fusion protein in order to avoid the frequent problem of low RED expression in tumor cells. This constructed protein is the fusion of two human proteins namely CYP2B6 and the human RED resulting in a single protein able to transfer electrons from NADPH right through to the heme moiety of the protein to enable metabolism of CYP2B6 substrates. In order to achieve high levels of expression in mammalian cells, the proteins were cloned into adenoviral vectors by homologous recombination. CPA belongs to the oxazaphosphorine class of molecules 6,7 and remains a widely used cytotoxic agent for the treatment of both solid tumors and hematological malignancies. It is used for the treatment of breast cancer, as a critical component of the CMF regimen, in the treatment of patients with non-Hodgkin's lymphoma, a variety of bone and soft tissue sarcomas, and acute lymphoblastic leukemia.
G ene-directed enzyme prodrug therapy (GDEPT) 1,2 is an emerging strategy used to improve the selectivity of cancer chemotherapy. This is accomplished through tumor-specific activation of noncytotoxic prodrugs to active drugs by drug-metabolizing enzymes. The general scheme consists of transfection of tumor cells with an enzyme responsible for the bioactivation of a noncytotoxic prodrug and treatment with the prodrug: only cells expressing the transfected drug-metabolizing enzyme can metabolize the prodrug into cytotoxic metabolites, leading to cell death. The use of viral vectors for transgene introduction is more specifically referred to as virusdirected enzyme prodrug therapy (VDEPT). Following promising early results of a P450-based GDEPT strategy, 3 using the rat 9L gliosarcoma cell line, cyclophosphamide (CPA) as a prodrug and CYP2B1 as the prodrug activating enzyme, our approach was to improve the strategy by activating CPA with cytochrome P450 2B6 (CYP2B6) 4, 5 or a CYP2B6/NADPH cytochrome P450 reductase (RED) fusion protein in order to avoid the frequent problem of low RED expression in tumor cells. This constructed protein is the fusion of two human proteins namely CYP2B6 and the human RED resulting in a single protein able to transfer electrons from NADPH right through to the heme moiety of the protein to enable metabolism of CYP2B6 substrates. In order to achieve high levels of expression in mammalian cells, the proteins were cloned into adenoviral vectors by homologous recombination. CPA belongs to the oxazaphosphorine class of molecules 6, 7 and remains a widely used cytotoxic agent for the treatment of both solid tumors and hematological malignancies. It is used for the treatment of breast cancer, as a critical component of the CMF regimen, in the treatment of patients with non-Hodgkin's lymphoma, a variety of bone and soft tissue sarcomas, and acute lymphoblastic leukemia. 8 CPA is a therapeutically inactive prodrug that requires bioactivation by CYP to exert its antitumor function. The primary 4 0 hydroxy metabolite is formed in the liver in a reaction mainly catalyzed by human CYP2B6, 5, 9, 10 and is in equilibrium with its ring opened tautomer, aldophosphamide. 4-Hydroxycyclophosphamide undergoes spontaneous decomposition both in the circulation and within the target tumor cells, to yield acrolein and phosphoramide mustard. The electrophilic mustard exhibits DNA crosslinking activity that eventually leads to apoptotic cell death. 11, 12 In conventional chemotherapy, the active metabolites have to travel to the often distal tumor site to exert their cytotoxic effect. Therefore, high doses of CPA are used (up to 7 g/m 2 ) 8 to ensure that the levels of cytotoxic metabolites are sufficient at the tumor sites. These doses of CPA may result in toxicity (neurotoxicity, cardiotoxicity and bone marrow suppression). Local delivery of CYP and CPA should increase selectivity of the chemotherapeutic regime while lower doses of CPA would be required, reducing the risk of drug-associated toxicity. 13 The primary 4 0 hydroxy metabolite is diffusible and therefore capable of entering most neighboring cells, even if they are uninfected. Once inside the cells the activated metabolite spontaneously decomposes into the cytotoxic compounds, acrolein and phosphoramide mustard.
14 This bystander effect, the process by which cytotoxicity can be exerted to nontransduced cells, 15 is important when one considers the sometimes low efficiency of gene transfer; furthermore, in CYP GDEPT, the bystander effect occurs even in the absence of direct cell-cell contact. 2, 14 The CYP system consists of two protein components, the heme-containing P450 and the flavoprotein RED both embedded in the phospholipid bilayer of the endoplasmic reticulum, 16 which facilitates their interaction. RED is a FAD-and FMN-containing enzyme encoded by a single gene, which catalyses the transfer of electrons, from NADPH, required for all microsomal CYP-dependent enzyme reactions. A single form of RED exists for all CYP isoforms and RED can transfer electrons much faster than CYP can use them, which could account for the low ratio of RED to CYP (1:10) in liver microsomes. 17, 18 Within tumors, GDEPT results in high levels of CYP expression and the RED moiety can be rate-limiting with respect to CYP-catalyzed enzyme reactions, and therefore prodrug bioactivation. 19 Since the expression of both CYP2B6 and that of RED is heterogeneous in tumors, 20 the co-expression of both proteins could significantly improve the success of this strategy. Co-expression can be achieved either as two separate proteins 19 or with the construction of a fusion protein linking CYP2B6 and RED in one gene. Previous efforts to fuse the two genes have resulted in active proteins; [21] [22] [23] [24] [25] however, fusion proteins have never been expressed in mammalian cells and RED has never been used in association with CYP2B6. Finally, the notion of fusing two human proteins should not produce a host immune response.
In this study, replication-defective adenoviral vectors were used to infect pulmonary cell lines with the various constructs. Other delivery methods reported include retroviral constructs, 26 oncolytic vectors 13, 27 and direct implantation of encapsulated CYP-engineered cells. 28, 29 However, the ability of adenoviral vectors to infect both dividing and nondividing cells increases the proportion of infected cells. Since adenoviral vectors do not integrate into the host chromosomes, there is no risk of integration and mutagenesis of infected host tissue.
The adenoviral vectors expressing CYP2B6, RED and the CYP2B6/RED fusion protein were infected into three pulmonary tumor cell lines in order to develop a therapeutic strategy for lung cancer. After the presence of the proteins was established, pulmonary cell lines infected with the fusion protein proved to be more sensitive to CPA treatment and the fusion protein was more effective than CYP2B6 alone. The fusion protein also conveyed a higher RED activity to cells compared to CYP2B6. Our results show that although the transfer of electrons in the constructed fusion protein is not optimal, electrons are successfully transferred from the flavin moiety to the heme in the CYP fragment of the protein and the use of the fusion protein is feasible and efficient even in cells lacking endogenous RED expression.
Materials and methods

Chemicals and reagents
CPA, cytochrome c, NADPH, glutathione, CDNB, acetaldehyde, and PVP were obtained from SigmaAldrich, France, anti-rat RED antibody was purchased from Daiichi pure chemicals Co. Ltd, Japan, and Swine anti-rabbit immunoglobulins and rabbit anti-goat immunoglobulins were from DAKO A/S, Denmark.
Cell lines
The three pulmonary cell lines (Calu-6, NCI-H460, A549) a kind gift from Oncodesign (Dijon, France) are epithelial tumor cell lines. One hepatoma cell line (HepG2) 30 was also used. Pulmonary cell lines were cultured in RPMI containing 10% fetal bovine serum (FBS) and supplemented with penicillin (200 U/ml), streptomycin (50 mg/ ml) and fungizone (0.5 mg/ml). HepG2 cells were cultured in 50%/50% DMEM and HamF12 medium containing 10% FBS and supplemented with penicillin (200 U/ml), streptomycin (50 mg/ml) and fungizone (0.5 mg/ml).
Construction of fusion protein
CYP2B6
5 and human RED were subcloned into plasmid vectors pCEP4 and pUC18, respectively. (The RED/ pUC18 was a kind gift of Dr P Urban.) Restriction sites and a linker sequence were introduced using PCR primers. CYP2B6 was amplified introducing a BamHI site 5 0 and a XhoI site 3 0 using the following primer set 5 0 cggatccatggagctcagcgtcct3 0 2B6up(BamHI) and 5 0 ccgctcgagcggggcaggaagcggatctgg3 0 2B6low(XhoI), these primers amplified the entire CYP2B6 until TGA-1 amino acid. The PCR conditions were a first 10 minutes step at 941C, then 30 rounds of 941C 30 seconds, 611C 30 seconds and 721C 1 minute 30 seconds, followed by a final extension of 10 minutes. The soluble part of the RED protein from bp 171 until the stop codon TAG was amplified using a conventional PCR thermocycler introducing an XhoI site 5 0 and a XbaI site 3 0 using the following primer set 5 0 ccgctcgagcacgattcagacattgacctcc VDEPT using a CYP2B6/reductase fusion protein M Tychopoulos et al tctg3 0 Redup(XhoI) and 5 0 gctctagagcctagctccacacgtccaggg agtagc3 0 Redlow(XbaI). The PCR conditions were 10 minutes at 941C, then 30 rounds of 941C for 30 seconds, 681C for 30 seconds and 721C for 1 minutes 30 seconds, followed by a final extension of 10 minutes at 721C. All PCRs were performed using Taq polymerase (Perkin Elmer) and MgCl 2 at a final concentration of 2 mM. The PCR products were purified (Qiagen PCR purification kit) and digested with the respective enzymes, CYP2B6 was cloned into the plasmid expression vector pcDNAI (Invitrogen) using the restriction sites BamHI and XhoI, subsequently RED was cloned into the sites XhoI and XbaI. A ser-ser-thr linker sequence was introduced between the two proteins (Fig 1) . The construct was sequenced using an automatic Perkin Elmer sequencer to ensure that the correct reading frame was retained.
RT-PCR
The presence of CYP2B6 was evaluated in the pulmonary cell lines using RT-PCR. RNA samples were prepared from each cell line using Qiagen RNeasy spin colmns, 5 mg of total RNA were used for the subsequent reverse transcription, and total human liver RNA was used as a positive control. Oligo (dT) primers (3 ml, 100 ng/ml) were added to the diluted RNA sample, then after heating at 651C a 5 Â RT buffer (Promega), 2 ml dNTPs (100 mM) and 1 ml MMLV-RT (Promega) were added in order. The solution was incubated at 421C for 1 hour, and heated at 951C before PCR reactions. Four sets of PCR primers were used: (i) SpeU2B6 and SpeL2B6 were used to amplify a specific region of 163 bp in the 3 0 untranslated region of CYP2B6 that enables the differentiation of CYP2B6 from all other members of the CYP2B family including CYP2B7; (ii) ATG2B6 and TGA2B6 were used to amplify the entire coding sequence of CYP2B6; (iii) U32B6 and L62B6 amplified a 690 bp fragment of the CYP 2B6 coding region; and (iv) U42B6 and L62B6 amplified a 437 bp fragment of the CYP2B6 coding region. A primer set that amplifies a 500 bp region within the Calnexin coding region was used as a positive control to evaluate the quality of the RT reaction.
Adenoviral infections
CYP2B6, human RED and the constructed fusion protein (CYP2B6/RED) were all cloned into serotype 5 adenovirus, which were provided by the vector core of the University of Nantes supported by the ''Association Franc¸aise contre les myopathies'' (AFM). The recombinant adenoviral vectors were generated by homologous recombination between a shuttle vector (pTrack-CMV) and the adenoviral backbone vector (pAdEASY-1). 31 The deletion of the adenoviral E1 renders the virus unable to produce infectious viral particles in target cells, and deletion of the E3 region is dispensable for viral production since it encodes proteins involved in evading host immunity. Both these deletions ensure the safety of this method of delivery. The efficiency of infection for each cell line was evaluated using a reporter gene in this Figure 1 Construction of the CYP2B6/RED fusion protein linker. Constuction of the CYP2B6/Red fusion protein as described under ''Materials and methods''. XhoI sites were introduced by PCR in both genes in order to fuse by ligation. CYP2B6 remains intact up until TGA-1, while the first 56 amino acids of the human reductase (amino-terminal membrane anchoring region) were cleaved leaving only the soluble moiety of the reductase. The XhoI sites introduced in the two genes gave place to a ser-ser-thr linker upon ligation as previously described. The fused gene was ligated into the pCDNA1 plasmid vector (Invitrogen).
VDEPT using a CYP2B6/reductase fusion protein M Tychopoulos et al case, Ad-lacZ. Each cell line was infected with a range of multiplicity of infection (MOI) between 2 and 500. After 24 hours, the cell medium was aspirated and 0.5% glutaraldehyde was added to the cells for 2 minutes. The cells were subsequently washed twice with 0.9% NaCl and cells were incubated at 371C for 6 hours with 2 ml of X-gal coloring solution. The number of infected (colored) cells was compared to the total cell number to establish the infection efficiency, and the minimum adenoviral concentration to achieve an infection of over 90% was used for subsequent infections for each cell line. The standard infection procedure consisted of diluting the desired adenoviral quantity into cell culture medium (with 2% FBS). Cells were incubated for 4 hours with the adenoviral constructs and then reconstituted in cell culture medium.
Northern blots
Total RNA from the cultured cell lines was extracted using the RNeasy Midi kit (Qiagen Courtaboeuf, France). Total RNA (10 mg), prepared from cultured cell lines, was subjected to electrophoresis in a denaturing formaldehyde 1.2% agarose gel and was subsequently transferred onto a nitrocellulose membrane, and hybridized with full-length cDNA radiolabelled probes of either CYP2B6 or RED. The relative intensities of the hybridization signals were detected by Phosphorimager Storm 840 (Amersham Biosciences, France). Total liver RNAs were used as positive control for both CYP2B6 and RED.
Microsomal preparation
Cells were cultivated for 3 days after infection, in order to produce sufficient quantities of protein. Cells were then trypsinized and washed twice with phosphate-buffered saline (PBS), and the cellular pellet was resuspended in STE buffer (0.25 mM Sucrose, 10 mM Tris, 1 mM EDTA pH 7.4) containing antiproteases (Roche diagnostics GmbH, Germany) and sonicated two times 20 seconds. The sonicated lysate was centrifuged at 9000 g for 20 minutes, and subsequently the supernatant was centrifuged at 100,000 g for 1 hour. The 100,000 g pellet containing the microsomes was resuspended in buffer (100 mM NaPO4, 10 mM MgCl2, 20% Glycerol (w/v) at pH 7.4), aliquoted and frozen at À801C.
Western blots
Microsomal proteins (20 mg, prepared from the cultured cell lines) were loaded onto a 9% SDS/polyacrylamide gel. The proteins were transferred onto a nitrocellulose membrane, blocked with 2% polyvinyl-pyrrolidone (PVP) and probed with a polyclonal anti-CYP2B6, 5 obtained in our lab after immunization of female New Zealand rabbits as previously described, 32 or a polyclonal antirat RED antibody (Daiichi pure chemicals Co. Ltd, Japan). After washing membranes, a secondary antibody linked to horseradish peroxidase (HRP) was used and membranes were developed using an ECL detection kit (Amersham). Yeast microsomes expressing CYP2B6 5 were used as a positive control for the anti-CYP2B6 antibody, while purified rat RED was used as a positive control for RED.
P450 difference spectrum
The P450 difference spectrum 33 was obtained by treating microsomes prepared from the infected cell lines with the reducing agent sodium dithionite and bubbled with CO in the sample cuvette while adding only the reducing agent to microsomes in the reference cuvette. Several grains of sodium dithionite were added to both reference and sample cuvettes and the baseline reduced spectrum was recorded, CO was then bubbled through the sample cuvette and the reduced difference spectrum was registered.
RED activity assay
RED activity was measured in the cellular microsomal fraction. The NADPH-dependent reduction of cytochrome c by RED was assayed as previously described. 34 Cytochrome c was added at a final saturating concentration of 80 mM and RED activity was calculated as nmol cytochrome c reduced/mn/mg using e ¼ 21 mM À1 cm À1 at 550 nm
Glutathione-S-transferase (GST) activity
GST activity was assayed in the cytosolic fraction of the cellular fractions (100,000 g supernatant) as previously described. 35 The enzyme assay is based the GST-mediated catalysis of the conjugation between Glutathione (GSH) and CDNB (1-chloro-2,4 dinitrobenzene) forming a dinitrophenyl thioether chromophore. CDNB is routinely used as the substrate permitting the detection of most GST isoforms.
ALDH activity
The cytosolic cellular fraction (100,000g supernatant) was used to assay the catalytic activity of ALDH (Aldehyde Dehydrogenase). ALDH catalytic activity was assayed by measuring the increase of absorbance at 340 nm due to the reduction of NAD þ to NADH following the oxidation of acetaldehyde to acetic acid. The assay method has previously been described, 36 but was adapted to a 96-well microplate reader using a final volume of 200 ml. ALDH1A1 which seems to have the highest activity for aldophosphamide oxidation (K m of 52 mM) also efficiently catalyses acetaldehyde (K m 50-100 mM). 37 In-vitro cytotoxicity assays Cells were infected in six-well plates at 4 Â 10 5 cells/well, with adenoviral constructs as previously described. Cells were then trypsinized and seeded into 96-well plates at 10 4 cells/well in triplicates. Cells infected with an adenoviral vector expressing LacZ were used as a control. Cells were treated with CPA 0-2 mM for 4 days, cell viability was assayed using the ''Celltitre 96 s AQ ueous One Solution Cell Proliferation Assay'' (Promega) according to the manufacturer's instructions. This colorimetric assay measures the dehydrogenase activity in the metabolically active mitochondria of viable cells. After the 4-day CPA treatment, 10 ml of One Solution Reagent (Promega) were added to the wells and cells were incubated for 2 hours at 371C, and subsequently the plates were read at 490 nm using a 960-well plate reader. Cell viability was expressed as the percentage of viable alive compared to those infected by control (Ad-LacZ) treated at identical CPA concentrations.
CPA induced cell toxicity was also evaluated by trypan blue inclusion assays. Cells were plated in six-well plates at 3 Â 10 5 , and after adenoviral infection cells were treated with CPA at 0-2 mM for 3-7 days. Both floating and adherent cells were collected, pooled and reconstituted in 200 ml medium, 50 ml of total cells were diluted 1:1 with trypan blue. The mortality due to CPA of the tumor cells was evaluated by counting the dead cells (blue) and expressing them as a percentage of total cells infected by Ad-LacZ at different CPA concentrations.
Bystander cytotoxicity assay
Bystander cytotoxicity was evaluated by two types of assays, both trypan blue exclusion and MTS colorimetric assays, which measures the dehydrogenase activity in the metabolically active mitochondria of viable cells, were performed on the cells.
For the trypan blue exclusion assay, HepG2 cells were infected with CYP2B6/RED (Ad-fus) or Ad-2B6 (and with the Ad-LacZ control) adenoviral constructs. After infection the cells were washed three times with PBS in order to eliminate traces of the adenoviral vectors. The infected cells were subsequently treated with CPA at 0.5 or 1.5 mM for 48 hours, the conditioned medium was collected and added to six-well plates preseeded with HepG2 cells at 1.5 Â 10 4 cells per well. Cells were treated with the conditioned medium for 7 days in duplicate, after which cell medium was discarded, cells were trypsinized and viability was counted using a trypan blue exclusion assay. Cell viability was expressed as the percentage of cells alive compared to those treated with the same concentration of CPA conditioned medium, in cells infected with Ad-LacZ.
Cell viability due to the bystander effect was also tested using an MTS assay in a conditioned medium concentration-dependent manner. In brief, HepG2 cells were infected with Ad-fus or Ad-2B6 (and with the Ad-LacZ as a control) adenoviral constructs. After infection the cells were washed three times with PBS in order to eliminate traces of the adenoviral vectors, and the following day treated with CPA at 1.5 mM for 48 hours. The CPA conditioned medium was diluted from 100 to 12.5% in fresh medium and added to preseeded HepG2 cells in duplicate (5 Â 10 3 cells/well), and cells were treated for 7 days after which the MTS test was performed. Cell viability was expressed as the percentage of cells alive compared to those infected by Ad-lacZ and treated with the same conditioned medium dilution.
Statistical analysis
In order to evaluate the cytotoxicity assays, data were subjected to one-way ANOVA analysis of variance. If data for a given concentration were significantly different Pr.05, the Student's t-test was performed to examine the statistical difference between the different infection combinations. The Student's t-test was subjected to the Bonferroni adjustment for multiple comparisons. In the results presented, Pr.05 is indicated as *, Pr.01 as ** and r.001 as ***.
Results
Endogenous expression of enzymes involved in the metabolism of CPA in pulmonary and hepatic cell lines
The presence of endogenous CYP2B6 mRNA was evaluated in the cell lines using Northern blots and RT-PCR. Northern blots were performed using the entire CYP2B6 coding sequence as a probe. Although the correct size band was present in the human liver RNA (positive control), the band was undetectable in the three pulmonary tumor cell lines' RNA and in HepG2. RT-PCR was subsequently used as a more sensitive method. The 500 bp Calnexin coding sequence fragment was successfully amplified from all samples ensuring the quality of the RT reaction. Although all four primer pairs successfully amplified the desired fragments from the human liver RNA sample (positive control), no amplification was observed in any of the pulmonary cell lines (data not shown) indicating the absence of CYP2B6 from the pulmonary tumor cell lines. The presence of the RED was first established in all cell lines by Northern blot (data not shown); however, in Northern blots where RED was overexpressed the bands were so intense that the endogenous RNA was barely visible. In order to establish more accurately the quantity of endogenous RED in the pulmonary cell lines, its catalytic activity was determined (Table 1 ). All cell lines had endogenous RED activity and HepG2 had a 2-5 times higher activity than that found in the pulmonary cell lines. Concerning ALDH and GST, the results of the endogenous catalytic activities of these Endogenous catalytic activities of the major enzymes implicated in the metabolism of CPA, in three tumor pulmonary cell lines, A549, H460, Calu-6 and one hepatoma, HepG2. The catalytic activities were carried out as described under 'Materials and methods'. Experiments were repeated three times, and standard deviations are presented in parentheses. In the case of GST catalytic activity the limit of detection was 25 nmol/mn/mg.
VDEPT using a CYP2B6/reductase fusion protein M Tychopoulos et al two enzymes, which are involved in a decrease in CPA toxicity, are summarized in Table 1 . In the case of ALDH, both HepG2 and A549 cell lines had higher levels of ALDH compared to Calu6 and H460. However, GST activity showed no significant difference between the pulmonary cell lines, but was below the limit of detection in HepG2 cells.
Adenoviral infection
The MOI in order to achieve a Z90% infection of cells was calculated by counting the amount of cells infected with lacZ (blue cells) compared to uninfected cells. All four cell lines were assayed; in HepG2, A549 and H460 an MOI of 200 was sufficient, while in Calu-6 a higher titer (300) of adenoviral particles was necessary to achieve the same order of infection. Taking into account the fact that the adenoviruses used as mammalian expression vectors are replication deficient, the duration of infection was evaluated by Northern blot in HepG2 cells using Ad-2B6. Expression of the infected CYP2B6 mRNA remained relatively high for up to 7 days after infection (data not shown). The verification of mRNA expression in the infected cells was performed by Northern blot using the entire coding sequence of either, CYP2B6 (Fig 2) or human RED as a probe. The detection of the protein was performed by Western blot using an anti-CYP2B6 5 ( Fig  3) and an anti-rat RED antibody, which crossreacts strongly with human RED.
Expression of CYP2B6 and RED in cells after infection
The presence of the CYP2B6 and RED transgenes in cells was evaluated by Northern blot and the presence of their protein by Western blot (Fig 3) . Human liver mRNA and microsomes respectively was used as a positive control. In the case of CYP2B6 mRNA, the band detected in human liver is larger than the CYP2B6 transgene due to the large size of the CYP2B6 3 0 UTR (approx 1700 bp).
Fusion protein
The fusion gene was sequenced after cloning to verify that the reading frame was preserved, and to ensure the correct linker sequence was introduced by PCR amplification. Fusion gene mRNA was detected by Northern blot using both CYP2B6 and RED, entire coding sequence probes (Fig 2) . The fusion gene consists of 3350 bp and the protein of 126 kDa. Detection of the fusion protein was respectively achieved by Western blot using both anti-CYP2B6 and anti-RED antibodies (Fig 3) . The ability of both these antibodies to detect a protein of the same size, which is endogenously absent in these cell lines, clearly showed that the fusion protein was being expressed. Furthermore, the detection of the mRNA by Northern blot further strengthens this conclusion.
RED activity
In cells infected by the adenoviral constructs containing RED in an engineered fused form, Ad-Fus, or the entire human RED, Ad-Red, there was an expected increase in RED activity (Table 2) . Cells infected with Adfus showed an increase in RED activity of up to five times (although in most cell lines up to three times), indicating that the RED moiety of the fusion protein is functional; however; cells infected with the entire human RED showed an increase in RED activity of up to 20 times in one cell line.
P450 difference spectrum
Both microsomes infected with either Ad-2B6 or Ad-Fus showed the characteristic 450-nm absorbance maximum of all cytochrome P450s. 38 The spectra were used to calculate the concentration of P450 in the microsomal preparation (Fig 4) . Since the lacZ control showed no absorbance peak at all at 450 nm, it was assumed that all the CYP in the preparation was due to the CYP2B6 or the fusion protein. The P450 concentration of the Ad-2B6 samples was 0.28 nmol/ml or 3.7 pmol/10 6 cells while that of the fusion protein sample was 0.46 nmol/ml or 6.1 pmol/10 6 cells. A complete CYP2B6 cDNA radiolabelled probe was used to detect the mRNA. Human liver RNA was used as a positive control; however, the mRNA of endogenous CYP2B6 is larger that that of the Ad-2B6 expressed RNA (due to 3 0 UTR size). Moreover due to the strong signal emmited by the expressed proteins the endogenous CYP2B6 mRNA can only be seen by over-exposing the membrane. The cDNA probes detects the CYP2B6 RNA of the correct size in both the entire (1500 bp) and the larger fused form (3300 bp). (b) Northern blot after infection with Ad-Red, Ad-Fus (CYP2B6/RED) and the Ad-lacZ control. A complete human reductase cDNA radiolabelled probe was used to detect the reductase mRNA. Total human liver RNA was used as a positive control; however, due to the strength of the signal of the expressed mRNAs, the endogenous mRNA is not visible unless the memebrane is overexposed. The radiolabelled probe detects both, entire reductase mRNA and the reductase moiety of the fusion protein.
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In vitro cytotoxicity assay
Results of the in vitro cytotoxicity assays are summarized in Figure 5 , while the IC 50 values and their statistical significance are presented in Figure 6 . No cytotoxicity was observed after treatment of uninfected cells with up to 5 mM CPA (data not shown). The infection of cells with the control vector Ad-lacZ resulted in a 10-15% increase in cytotoxicity compared to uninfected cells (depending on the cell line) independent of the CPA concentration and probably due to the toxicity of the adenoviral vectors. Therefore, cell viability has been expressed as the percentage of cells alive after each infection compared to those infected by Ad-lacZ and treated with the same CPA concentration. In the case of double infection a RED activity is expressed as nmol/mn/mg. The catalytic activity of reductase in the adenovirus infected cell lines. The catalytic activity of reductase was assayed, in cell microsomes, by the NADPH-dependent reduction of cytochrome c by RED as described under 'Materials and methods'. The catalytic activities were repeated three times (in duplicates), the standard deviation is presented in parentheses. The four tumor cell lines were infected with either of two constructs, Ad-Fus, containing the CYP2B6/RED fusion gene, and Ad-Red, containing the coding region of human RED. Infection by control AdlacZ did not increase the catalytic activity (data not shown). Similar results were obtained with trypan blue inclusion test performed on two cell lines, HepG2 and Calu-6, although the cytotoxic effect seemed stronger, and after 3 days of treatment, even Ad-2B6 alone resulted in 80% cytotoxicity once treated with 2 mM CPA. However, due to the increased sensitivity of this method, the difference between the cells lines and constructs was harder to evaluate.
In vitro evaluation of Bystander effect
The results presented in Figure 7 show that infection with Ad-2B6 and Ad-fus exerted a strong bystander effect on noninfected cells. Cells treated with CPA-conditioned medium at 1.5 mM resulted in approximately 80% cytotoxicity, nearly as significant as that of cells infected with Ad-fus treated with 2 mM CPA. However, the incubation time could account for this fact; in the case of bystander cytotoxicity, cells were treated for 7 days while in the direct CPA-sensitivity cytotoxicity assays cells were treated for 4 days. Similar results were obtained when evaluating cell viability via an MTS assay. The bystander effect remains a principle advantage of this GDEPT strategy since transfection efficiency of genes is still not perfected. The bystander effect in CYP-based GDEPT is independent of cell contact as can be seen by these results. Figure 5 MTS cytotoxicity assays on cell lines. CPA-induced cytotoxicity assays in the four cell lines infected by different adenoviral vectors expressing CYP2B6 (2B6), the human reductase (hRed) a fused form of the two proteins (fus) and the two proteins co-infected (2B6 þ hRed). Cytotoxicity was assayed using an MTS colorimetric test, which measures the dehydrogenase activity in the metabolically active mitochondria of viable cells, the procedure followed is described under ''Materials and methods''. Cell viability is expressed as the percentage of viable cells compared to those infected by the control vector (Ad-LacZ) treated at identical cyclophosphamide concentrations. The assays were repeated three times in duplicate and bars represent SD.
Discussion
Taking into account the importance of sufficient RED expression in the CYP-based GDEPT strategy 19 and the frequent low levels of expression of this enzyme in tumor cells, the concept of fusing the RED moiety to CYP2B6 and therefore creating a single transgene was explored. Expression of a single transgene simplifies the GDEPT strategy, allowing expression of both enzymes in the same cell. Using adenoviral vectors, the constructed CYP2B6/ RED fusion protein has been successfully expressed in all mammalian cell lines used in this study.
This CYP/RED fusion protein is the first P450 fusion protein expressed in mammalian cells, and moreover both fused moieties are of human origin. Natural CYP:RED fusion proteins exist containing both the heme domain of the CYP and the flavin domains of the RED where the electron transfer system seem to be efficient. The two major examples of natural fusion protein are nitric oxide synthetase 39 and P450 102 (initially named P450 BM3 ) isolated from Bacillus megaterium, 40 which is one of the most catalytically active forms of CYP. Several recombinant fusion proteins have also been constructed; however, previously reported fusion proteins were constructed in order to create ''self-sufficient enzymatic units for the study of P450 catalyzed reactions'' 23 , for direct measurement of catalytic activities in intact bacterial cells. The first published was a fusion of rat CYP1A1 and yeast RED 22 and was expressed in yeast. Since then several groups have constructed fusion proteins including human CYP3A4 fused to rat RED 21 and expressed them in bacteria 24, 25, 41 for functional studies. In our constructed CYP2B6/hRed fusion protein, as in all other reported artificial fusion proteins, the aminoterminal hydrophobic region of the RED (first 56 amino acids) has been deleted. This deletion similar to the cleavage induced by protease treatment resulted in a soluble enzyme that is active in the reduction of cytochrome c however not in that of cytochrome P450. 42 The amino terminal sequence is considered important for the anchorage of the RED to the endoplasmic reticulum membrane and is an important moiety for the interaction with cytochrome P450. Since the two proteins are fused the N-terminal of the RED is no longer required, the fusion protein is anchored to the membrane by the CYP2B6 N-terminal. Figure 6 IC 50 values of the four infected cell lines after CPA treatment. Cells were infected with CYP2B6 alone (solid bars), the CYP2B6/RED fusion protein (diagonally hatched bars), and both CYP2B6 and RED as separate entities (vertically hatched). The concentration at which 50% cytotoxicity was achieved was determined, the results are based on three experiments in duplicate, error bars represent the standard deviation. The cytotoxicity due to the control vector Ad-lacZ has been subtracted from each condition. Concerning statistical significance, * indicates a Pr.05 and **Pr.01.
The Ser-Ser-Thr linker used in this construct was chosen to enable cloning and has been previously described 43 in a study on the influence of different linker groups on the enzymatic activity of fusion proteins. The conclusion reached was that the number or the charge of amino acids in the linker region had a small effect, up to two-fold, on the rate of catalysis of the fusion protein. 23 Although the constructed fusion protein is active, the increase in RED activity it yields is 2.5-to four-fold, while the increase in RED catalytic activity by infection with the free RED is over seven-to 20-fold. These results are in concordance with the results of the cytotoxicity assays, showing in pulmonary cell lines that the fusion protein increases CPA cytotoxicity compared to CYP2B6 alone. However, infection with CYP2B6 and the RED as two separate entities resulted in increased CPA cytotoxicity in cells, mainly at low concentrations. From these results we could conclude that the conformation of the fusion protein is probably not optimal for the transfer of electrons, but that both moieties are functional and that the transfer of electrons from the flavin domains to the heme is accomplished within the fusion protein.
In our study we have infected this fusion protein into human cell lines and evaluated the cytotoxicity induced by CPA. Although infection with the fusion protein leads only to a three-fold increase in RED catalytic activity, the cytotoxicity results show that at higher CPA concentrations the fusion protein seems to induce nearly as much cytotoxicity as the co-infection of CYP2B6 and the RED. Furthermore, in one cell line at 2 mM the difference between the fusion protein and the co-infection is not significant, although the cell lines co-infected with the two proteins have a five-fold higher RED catalytic activity compared to those infected with the fusion protein. In the endoplasmic reticulum, endogenous CYP is in a large excess over the RED although the exact ratio varies dependent on the induction status of CYP, which exceeds that of the RED by 10:1 to 20:1. 17 Therefore, since CYP is always in excess of the RED it seems reasonable that an increase in the levels of RED expression would bring about a proportionally higher increase in CYP activity. In other words, the ratio of infected RED need not be equivalent to that of cytochrome P450. Effectively in the pulmonary cell lines with lower RED catalytic activity, the infection by the fusion protein significantly increases CPA-induced cytotoxicity compared to CYP2B6 alone. In the HepG2 cell line, which showed the highest levels of RED catalytic activity of the four cell lines, the introduction of the RED in its free or fused form did not increase significantly the cytotoxicity induced by CPA at concentrations higher or equal to 1 mM.
There is ample evidence available suggesting that both GSTs and ALDH intervene in the metabolism of CPA. 6 Some forms of ALDH catalyze the NADdependent oxidation of aldophosphamide to carboxyphosphamide bypassing the production of phosphoramide mustard leading to detoxification of CPA. GSTs seem to be responsible for the two types of Glutothionyl conjugates described, 4-GSCP (4-glutathionylCPA) and PMGS (monochloromonoglutathionylphosphoramide mustard), 44 both of which result in the detoxification of CPA. In our study, the overexpression of CYP2B6, in free or fused form, seemed to overcompensate for any differences in endogenous levels of either ALDH or GSTs. In the A549 cell line with the highest levels of ALDH, no significant difference was observed with respect to CPA induced cytotoxicity compared to the other infected pulmonary tumor cell lines. Although overexpression of either of these proteins (ALDH, GSTs) could drastically decrease CPA induced cytotoxicity, 45 the endogenous levels do not seem to interfere with the GDEPT strategy. These results are in disagreement with recently published results 46 where the A549 cell line could not be rendered sensitive to CPA treatment, where the authors hypothesized that this was due to higher ALDH levels. This discrepancy could be due to different culture conditions or the difference in the adenoviral constructs.
Bystander cytotoxicity is a key point of the CYP-based GDEPT strategy. The diffusible 4-hydroxy-cyclophosphamide metabolite is capable of entering neighboring cells where it is converted to phosphoramide mustard and can therefore provoke the death of uninfected cells. In the experiments performed, it was demonstrated that the diffusion of the 4-hydroxy-cyclophosphamide metabolite is independent of cell contact, since CPA-conditioned medium exerts an effect on uninfected cells. This result is in accordance with previous reports on CYP-based GDEPT bystander effect.
14 There is no significant difference between the bystander effect due to the fusion protein compared to CYP2B6 alone. This is probably due to the fact that experimental conditions are not optimal to differentiate between constructs, but were designed to establish the bystander effect. The importance of this strong bystander effect must be stressed since it can compensate for the low delivery efficiency of current vectors.
With 157,200 deaths alone in the US in 2003, lung cancer is by far the most lethal of all neoplasms. The 15% 5-year survival rate is very poor in comparison to other cancers; in addition, this number has not changed significantly over the past 30 years. Accordingly, it is not surprising to see that molecular characterization of lung cancer and the subsequent application of gene transfer methods has played a large role in the development of gene therapy over the last decade. 47 VDEPT has been previously used successfully at preclinical study level, clinical trials evaluating the efficiency of adenoviralmediated HSVth/GCV prodrug therapy in lung cancer were completed at the University of Pennsylvania. 48 CYPbased GDEPT has also showed initial promising results in treating pancreatic cancer, in phase I clinical trials using CYP2B1 and ifosfamide. 28 At this stage improved results in gene therapy depend on more efficient delivery systems; however, due to the heterogeneous nature of tumor cells correct molecular characterization of tumors is necessary. Strategies have to be elaborated that can overcome to some extent this heterogeneity. The constructed CYP2B6/ RED fusion protein has shown promising initial results concerning enzyme activity and cytotoxicity towards CPA treatment compared to CYP2B6 alone. It can be used to treat a larger range of tumor cells than CYP2B6 alone, without the necessity of co-infection. However, the catalytic activity of CYPs for the activation of CPA has to be improved. This can be achieved either by engineering the fusion protein in order to significantly increase its catalytic activity (since naturally occurring P450/RED fusion proteins are some of the most catalytically active cytochrome P450s), or by finding CYP2B6 mutants with increased catalytic properties.
